FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019687911> ?p ?o ?g. }

• W2019687911 abstract "Abstract Background Controlling and limiting the expression of short hairpin RNA (shRNA) by using constitutive or tissue-specific polymerase II (pol II) expression can be a promising strategy to avoid RNAi toxicity. However, to date detailed studies on requirements for effective pol II shRNA expression and processing are not available. We investigated the optimal structural configuration of shRNA molecules, namely: hairpin location, stem length and termination signal required for effective pol II expression and compared it with an alternative strategy of avoiding toxicity by using artificial microRNA (miRNA) scaffolds. Results Highly effective shRNAs targeting luciferase (shLuc) or Apolipoprotein B100 (shApoB1 and shApoB2) were placed under the control of the pol II CMV promoter and expressed at +5 or +6 nucleotides (nt) with reference to the transcription start site (TSS). Different transcription termination signals (TTS), namely minimal polyadenylation (pA), poly T (T5) and U1 were also used. All pol II- expressed shRNA variants induced mild inhibition of Luciferase reporters carrying specific targets and none of them showed comparable efficacy to their polymerase III-expressed H1-shRNA controls, regardless of hairpin position and termination signal used. Extending hairpin stem length from 20 basepairs (bp) to 21, 25 or 29 bp yielded only slight improvement in the overall efficacy. When shLuc, shApoB1 and shApoB2 were placed in an artificial miRNA scaffold, two out of three were as potent as the H1-shRNA controls. Quantification of small interfering RNA (siRNA) molecules showed that the artificial miRNA constructs expressed less molecules than H1-shRNAs and that CMV-shRNA expressed the lowest amount of siRNA molecules suggesting that RNAi processing in this case is least effective. Furthermore, CMV-miApoB1 and CMV-miApoB2 were as effective as the corresponding H1-shApoB1 and H1-shApoB2 in inhibiting endogenous ApoB mRNA. Conclusion Our results demonstrate that artificial miRNA have a better efficacy profile than shRNA expressed either from H1 or CMV promoter and will be used in the future for RNAi therapeutic development." @default.
• W2019687911 created "2016-06-24" @default.
• W2019687911 creator A5038524181 @default.
• W2019687911 creator A5040613970 @default.
• W2019687911 creator A5062059707 @default.
• W2019687911 creator A5070641629 @default.
• W2019687911 creator A5072847313 @default.
• W2019687911 creator A5078627834 @default.
• W2019687911 creator A5089477827 @default.
• W2019687911 date "2012-07-24" @default.
• W2019687911 modified "2023-10-07" @default.
• W2019687911 title "Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100" @default.
• W2019687911 cites W1502501099 @default.
• W2019687911 cites W1611419331 @default.
• W2019687911 cites W1647075334 @default.
• W2019687911 cites W1963563485 @default.
• W2019687911 cites W1971643509 @default.
• W2019687911 cites W1973924029 @default.
• W2019687911 cites W1974343787 @default.
• W2019687911 cites W1974808591 @default.
• W2019687911 cites W1980256191 @default.
• W2019687911 cites W1988110855 @default.
• W2019687911 cites W1991737083 @default.
• W2019687911 cites W2010835680 @default.
• W2019687911 cites W2013779414 @default.
• W2019687911 cites W2034500416 @default.
• W2019687911 cites W2056892724 @default.
• W2019687911 cites W2061311846 @default.
• W2019687911 cites W2072543946 @default.
• W2019687911 cites W2076510291 @default.
• W2019687911 cites W2078162078 @default.
• W2019687911 cites W2087453865 @default.
• W2019687911 cites W2099517096 @default.
• W2019687911 cites W2104146201 @default.
• W2019687911 cites W2107277218 @default.
• W2019687911 cites W2116660518 @default.
• W2019687911 cites W2117391818 @default.
• W2019687911 cites W2117841932 @default.
• W2019687911 cites W2124531879 @default.
• W2019687911 cites W2141157874 @default.
• W2019687911 cites W2153747430 @default.
• W2019687911 cites W2161222316 @default.
• W2019687911 cites W2168420463 @default.
• W2019687911 doi "https://doi.org/10.1186/1472-6750-12-42" @default.
• W2019687911 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3424168" @default.
• W2019687911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22827812" @default.
• W2019687911 hasPublicationYear "2012" @default.
• W2019687911 type Work @default.
• W2019687911 sameAs 2019687911 @default.
• W2019687911 citedByCount "20" @default.
• W2019687911 countsByYear W20196879112013 @default.
• W2019687911 countsByYear W20196879112014 @default.
• W2019687911 countsByYear W20196879112016 @default.
• W2019687911 countsByYear W20196879112017 @default.
• W2019687911 countsByYear W20196879112018 @default.
• W2019687911 countsByYear W20196879112019 @default.
• W2019687911 countsByYear W20196879112020 @default.
• W2019687911 countsByYear W20196879112021 @default.
• W2019687911 countsByYear W20196879112022 @default.
• W2019687911 crossrefType "journal-article" @default.
• W2019687911 hasAuthorship W2019687911A5038524181 @default.
• W2019687911 hasAuthorship W2019687911A5040613970 @default.
• W2019687911 hasAuthorship W2019687911A5062059707 @default.
• W2019687911 hasAuthorship W2019687911A5070641629 @default.
• W2019687911 hasAuthorship W2019687911A5072847313 @default.
• W2019687911 hasAuthorship W2019687911A5078627834 @default.
• W2019687911 hasAuthorship W2019687911A5089477827 @default.
• W2019687911 hasBestOaLocation W20196879111 @default.
• W2019687911 hasConcept C101762097 @default.
• W2019687911 hasConcept C104317684 @default.
• W2019687911 hasConcept C105580179 @default.
• W2019687911 hasConcept C111335760 @default.
• W2019687911 hasConcept C138885662 @default.
• W2019687911 hasConcept C142575336 @default.
• W2019687911 hasConcept C145059251 @default.
• W2019687911 hasConcept C150194340 @default.
• W2019687911 hasConcept C153911025 @default.
• W2019687911 hasConcept C166703698 @default.
• W2019687911 hasConcept C169663058 @default.
• W2019687911 hasConcept C173396325 @default.
• W2019687911 hasConcept C179926584 @default.
• W2019687911 hasConcept C190232843 @default.
• W2019687911 hasConcept C2776449523 @default.
• W2019687911 hasConcept C41895202 @default.
• W2019687911 hasConcept C54009773 @default.
• W2019687911 hasConcept C55493867 @default.
• W2019687911 hasConcept C64350747 @default.
• W2019687911 hasConcept C67705224 @default.
• W2019687911 hasConcept C70916841 @default.
• W2019687911 hasConcept C86803240 @default.
• W2019687911 hasConcept C95444343 @default.
• W2019687911 hasConceptScore W2019687911C101762097 @default.
• W2019687911 hasConceptScore W2019687911C104317684 @default.
• W2019687911 hasConceptScore W2019687911C105580179 @default.
• W2019687911 hasConceptScore W2019687911C111335760 @default.
• W2019687911 hasConceptScore W2019687911C138885662 @default.
• W2019687911 hasConceptScore W2019687911C142575336 @default.
• W2019687911 hasConceptScore W2019687911C145059251 @default.
• W2019687911 hasConceptScore W2019687911C150194340 @default.
• W2019687911 hasConceptScore W2019687911C153911025 @default.

• next